KNSA
Kiniksa InternationalDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Positive pivotal/late-stage toplines or a strategic partnership that materially de-risks programs and extends cash runway would prompt rapid multiple expansion and re-rating toward the bull target.
Posture
Defensive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-27.
What can break
Clinical trial failure or safety signal
Momentum
80
Value
60
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $36.49 · Bull $54.74 · Bear $18.25
Earnings
2026-07-27
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $68.13
Why
Momentum80 · Δ7d -1.4
Value60 · Δ7d -0.0
Sentiment5 · Δ7d -1.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
80
26% active weight
Current posture
7d trendFlat
Δ7d
-1.4
Δ21d
+3.2
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
5
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
-5.9
Why this grade
Composite grade D. Momentum 80.3 / Value 60.0 / Sentiment 4.6
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$4.81B
Beta
0.06
Shares Out
76.94M
P/E (TTM)
91.6
P/S (TTM)
5.20
P/FCF (TTM)
30.59
Rev YoY
+55.5%
EPS YoY
+144.5%
Gross Margin
+54.6%
Op Margin
+6.4%
Net Debt
-$404.58M
Current Ratio
3.79
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology